Provider: Silverchair
Database: AmericanMedicalAssociation
Content: text/plain; charset="UTF-8"

TY  - JOUR
AU  - Harris, Emily
T1  - Safety Concerns Put a Stop to Maternal RSV Vaccine Study
PY  - 2024
Y1  - 2024/05/07
DO  - 10.1001/jama.2024.5155
JO  - JAMA
JA  - JAMA
VL  - 331
IS  - 17
SP  - 1439
EP  - 1439
SN  - 0098-7484
AB  - A vaccine given during pregnancy that prevents respiratory syncytial virus (RSV) in infants was about 66% effective at protecting against RSV-associated respiratory illness, and about 69% effective at protecting against severe disease, according to a study in the New England Journal of Medicine. The data came from a randomized clinical trial involving more than 5000 pregnant people and their infants in 24 countries.However, the researchers stopped the trial early because of an increased risk of preterm births. About 7% of infants whose birthing parent had received the vaccine were born before 37 weeks compared with roughly 5% of infants whose birthing parent had received a placebo. The higher rate of preterm births was “predominantly observed” among low- and middle-income countries between August and December 2021, and was not explained by SARS-CoV-2 infection or COVID-19 vaccination, the researchers noted.
Y2  - 5/20/2024
UR  - https://doi.org/10.1001/jama.2024.5155
ER  -